PetMed Express Q3 net loss $2.0M; completes sales tax restatement

PETMED EXPRESS INC

2024-FY EPS reported -$0.37 vs consensus -$0.01 ▼ miss (-7154.9%)

Revenue $65.3M, up 11% YoY, driven by PetCareRx acquisition; legacy sales declined.
Net loss $(0.10)/diluted share vs $(0.01) loss last year; Adjusted EBITDA $924K vs $2.7M.
Cash $49.4M, no debt; AutoShip & Save and PetPlus made up 52% of revenue (vs 42% a year ago).
Restatement completed; sales tax liability now $24.2M from prior $7.8M as of Mar 2023.
Company now current on all SEC filings; restatement had no impact on FY2024 revenue or cash.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PETMED EXPRESS INC reported fiscal third quarter 2024 results: revenue Net sales for the quarter ended December 31, 2023, were $65.3 million, net income Net loss for the quarter ended December 31, 2023 was $2.0 million, EPS $(0.10) per diluted share.

Period: fiscal third quarter 2024
Revenue: Net sales for the quarter ended December 31, 2023, were $65.3 million
Net income: Net loss for the quarter ended December 31, 2023 was $2.0 million
EPS: $(0.10) per diluted share
Result: reported results

Exact text from the filing

Net sales for the quarter ended December 31, 2023, were $65.3 million, compared to $58.9 million for the third quarter in the prior year, an increase of 11% year over year.

View on SEC.gov

322 earnings releases filed in the last 30 days. Browse all earnings releases →

PETMED EXPRESS INC filing history →

Source: SEC EDGAR

accession 0001040130-24-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.